ciglitazone has been researched along with Joint Diseases in 1 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Joint Diseases: Diseases involving the JOINTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Whereas high dosage of full agonists may expose RA patients to cardiovascular adverse effects, the proof of concept that PPAR agonists have therapeutical relevance to OA may benefit from an epidemiological follow-up of joint lesions in diabetic or hyperlipidemic patients treated for long periods of time with glitazones or fibrates." | 2.44 | [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists]. ( Bianchi, A; Jouzeau, JY; Koufany, M; Moulin, D; Netter, P; Sebillaud, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jouzeau, JY | 1 |
| Moulin, D | 1 |
| Koufany, M | 1 |
| Sebillaud, S | 1 |
| Bianchi, A | 1 |
| Netter, P | 1 |
1 review available for ciglitazone and Joint Diseases
| Article | Year |
|---|---|
[Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
Topics: Animals; Arthritis, Rheumatoid; Chromans; Dimerization; Extracellular Matrix; Humans; Hypoglycemic A | 2008 |